English
Multiple sclerosis (MS) is a common neurological disease in young adults, but its molecular mechanisms remain unclear. SNPs in genes regulating RNAPII pause-release and elongation have been linked to MS risk, but this connection has not yet been explored. Our initial analysis of a small cohort of MS patients revealed that defective RNAPII pause-release/elongation was present in about one-third of the samples. While cells can survive this transcriptional defect, it leads to significant gene expression changes, including overexpression of short pro-inflammatory genes due to deregulated RNAPII initiation, and underexpression of longer genes, which suffer from poor RNAPII processivity (Porozhan et al, LSA, 2024). This single defect thus contributes to multiple transcriptional abnormalities associated with MS. In Task 1, we will investigate the effects of the transcriptional reprogramming on T-cell activation, proliferation, and programmed cell death in vitro. We will also further characterize the epigenetic mechanisms that control RNAPII pause-release and elongation. In Task 2, we will leverage an HP1a/Cbx5 knockout mouse model, which has unexpectedly replicated the transcriptional defects seen in MS patients and demonstrated increased susceptibility to experimental autoimmune encephalomyelitis (EAE). This model will allow exploring the downstream consequences of defective RNAPII elongation on the immune system and susceptibility to neuroinflammatory disorders. In Task 3, we will assess the diagnostic potential of measuring RNAPII pause-release activity in MS patient cohorts, aiming to establish novel biomarkers. Our consortium will associate specialists in epigenetics and transcriptomics with translational immunologists, while keeping strong contacts with MS clinicians. We expect to provide pioneering insights into the transcriptional mechanisms driving MS and open avenues for better disease management.
